Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6509857 | 0.80 | OGFRL1 (0.35) | HSD11B1CNR2MAOAMAOBKDM4E | |
| SCHEMBL13285011 | 0.74 | CNR2 (0.49) | HSD11B1CNR2MAOAMAOB | |
| SCHEMBL9906605 | 0.71 | CYP2A13 (0.41) | MAPTUSP2CYP2A13MAPK1KDM4E | |
| SCHEMBL5157056 | 0.70 | HSD11B1 (0.53) | HSD11B1CNR2 | |
| SCHEMBL6502476 | 0.68 | HSD11B1 (0.57) | HSD11B1CNR2 | |
| SCHEMBL15008914 | 0.67 | CYP2A13 (0.54) | HSD11B1MAPTUSP2CYP2A13MAPK1 | |
| SCHEMBL25485065 | 0.66 | MAOA (0.40) | MAOAMAOB | |
| SCHEMBL6504279 | 0.66 | HSD11B1 (0.51) | HSD11B1CNR2 | |
| SCHEMBL20158970 | 0.65 | MAOA (0.40) | MAOAMAOB | |
| SCHEMBL20158969 | 0.65 | MAOA (0.40) | MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261290-A1 | Novel compounds of proline and morpholine derivatives | CHENG HENGMIAO | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261290-A1 | Novel compounds of proline and morpholine derivatives | CYP11B1, HSD11B1, CYP11B2 | HSD11B1 2/4885MAPT 2038/4885USP2 3806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.